Extension of the in vivo half-life of endostatin and its improved anti-tumor activities upon fusion to a humanized antibody against tumor-associated glycoprotein 72 in a mouse model of human colorectal carcinoma

Endostatin is an endogenous angiogenesis inhibitor that exhibits potential anti-tumor efficacy in various preclinical animal models. However, its relatively short in vivo half-life and the long-term, frequent administration of high doses limit its widespread clinical use. In this study, we evaluated...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Sang-Hyun, Jeung, In Cheul, Park, Tae Woo, Lee, Kyungmin, Lee, Dong Gwang, Cho, Young-Lai, Lee, Tae Sup, Na, Hee-Jun, Park, Young-Jun, Lee, Hee Gu, Jeong, Mun Sik, Bae, Kwang-Hee, Lee, Sang Chul, Lee, Hyo Jin, Kwon, Young-Guen, Hong, Hyo Jeong, Kim, Jang-Seong, Min, Jeong-Ki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4466677/
https://www.ncbi.nlm.nih.gov/pubmed/25762629

Ejemplares similares

Ejemplares similares